Skip to content
10-K

Annual Report

4D Molecular Therapeutics, Inc. FDMT

0001193125-26-114075

← back to feed
Filed
Mar 18, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 57.93M sh
Shares Diluted FY 2025 · Dec 31, 2024 53.94M sh
Capex FY 2025 · Dec 31, 2025 $536K
Capex FY 2025 · Dec 31, 2024 $3.79M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$109.08M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$134.59M
Cash And Equivalents FY 2025 · Dec 31, 2025 $60.24M
Cash And Equivalents FY 2025 · Dec 31, 2024 $149.34M
Stockholders Equity FY 2025 · Dec 31, 2025 $505.66M
Stockholders Equity FY 2025 · Dec 31, 2024 $510.61M
Stockholders Equity FY 2025 · Dec 31, 2023 $307.83M
Current Liabilities FY 2025 · Dec 31, 2025 $43.99M
Current Liabilities FY 2025 · Dec 31, 2024 $29.15M
Total Liabilities FY 2025 · Dec 31, 2025 $61.05M
Total Liabilities FY 2025 · Dec 31, 2024 $49.78M
Current Assets FY 2025 · Dec 31, 2025 $413.13M
Current Assets FY 2025 · Dec 31, 2024 $434.93M
Total Assets FY 2025 · Dec 31, 2025 $566.71M
Total Assets FY 2025 · Dec 31, 2024 $560.38M
Eps Diluted FY 2025 · Dec 31, 2025 −$2.42
Eps Diluted FY 2025 · Dec 31, 2024 −$2.98
Eps Basic FY 2025 · Dec 31, 2025 −$2.42
Eps Basic FY 2025 · Dec 31, 2024 −$2.98
Sga Expense FY 2025 · Dec 31, 2025 $49.06M
Sga Expense FY 2025 · Dec 31, 2024 $46.58M
Net Income FY 2025 · Dec 31, 2025 −$140.11M
Net Income FY 2025 · Dec 31, 2024 −$160.87M
Operating Income FY 2025 · Dec 31, 2025 −$159.55M
Operating Income FY 2025 · Dec 31, 2024 −$187.84M
Revenue FY 2025 · Dec 31, 2025 $85.21M
Revenue FY 2025 · Dec 31, 2024 $37K